HEALTH

Clarion Brands adds probiotic Florajen to product lineup

BY Michael Johnsen

TREVOSE, Pa. – Clarion Brands, a portfolio company of Swander Pace Capital, on Tuesday announced the acquisition of the probiotic brand Florajen.

“Florajen is the perfect addition to our portfolio,” stated Gary Downing, CEO of Clarion Brands. “We have a longstanding history of partnering with healthcare professionals to provide consumers with trusted solutions to their everyday health needs, and Florajen represents both an exciting and strategic next step for us.”

Florajen joins Lipo-Flavonoid, an OTC product for ringing in the ears (tinnitus), and Certain Dri, an OTC treatment for controlling excessive underarm sweating (hyperhidrosis).

Florajen is a high-potency probiotic dietary supplement that contains high concentrations of the same beneficial microorganisms that occur naturally in healthy people to help maintain the balance of flora in the intestinal tract. Florajen probiotic supplements, taken concurrently with antibiotics, can help avoid unpleasant side effects and aid in digestive health.

“The founders of Florajen have created a remarkably effective product with demonstrated success in helping consumers of all ages maintain the natural microbial balance the body needs to stay healthy,” Downing added. “We’re eager to not only continue the successful marketing approach established by Florajen’s founders, but to intensify the scope and reach within the professional community and leverage our strong pharmacy relationships to increase awareness of, and access to, Florajen.”

“When we partnered with Gary to establish Clarion in 2014, our mission was to build a leading platform in the OTC and supplement category,” said Mo Stout, a managing director at Swander Pace Capital. “Acquiring brands like Florajen that are category leaders in growing personal health niches is a key part of that strategy.”

The Clarion Brands leadership team has a successful track record of reenergizing iconic heritage brands through strategic marketing and merchandising efforts. Downing and VP marketing Jennifer Moyer were previously leading Insight Pharmaceuticals, parent company of leading women’s health brands Monistat and e.p.t, as well as Bonine, Nix and Sucrets, among others. In 2014, Insight Pharmaceuticals was acquired by Prestige Brands for $750 million.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

88 Health Products addresses fructose malabsorption with FructosAid

BY Michael Johnsen

ANN ARBOR, Mich. – 88 Health Products on Monday introduced FructosAid brand xylose isomerase to address fructose malabsorption. The supplement is available through Swanson Health Products and on Amazon.com.

Previously known as dietary fructose intolerance, fructose malabsorption is a digestive complication that can result in abdominal pain, bloating, gas and diarrhea. While experts suggest that up to one third of the general population may be affected, fructose malabsorption remains an under-recognized health challenge with few over-the-counter solutions.

Fructose absorption is limited by the availability and activity of enzymes and transporters sufficient to break down and absorb fructose. FructosAid is the U.S. brand name for xylose isomerase (XI), an enzyme that converts dietary fructose in the gut into glucose the body can readily absorb and use.

FructosAid is produced under patent by Sciotec Pharma of Austria, a division of STADA Arzneimittel, and is marketed in the U.S. by 88 Health Products under exclusive license. XI is sold in Europe under the brand name Xylosolv.

Fructose malabsorption should not be confused with hereditary fructose intolerance.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Perrigo launches store brand equivalent for Zegerid OTC

BY Michael Johnsen

DUBLIN – Perrigo announced Monday that the U.S. Food and Drug Administration has approved the company's ANDA for omeprazole and sodium bicarbonate capsules, 20mg/1100mg.  This approval will initiate the first store brand launch of an equivalent product to Zegerid OTC capsules.

Shipments to retail customers have already commenced.

Zegerid OTC is indicated for the treatment of frequent heartburn. National brand sales for the twelve months ending June 2016 were $27 million.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?